Saturday 17 October 2026
Export TPST’s income statement to Excel — free account
Tempest Therapeutics, Inc.
TPST Healthcare Biotechnology
In the quarter to June 2026, EPS grew 83.6% and free cash flow grew 67.0%, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.
0.62
0.02
−3.13%
Follow TPST
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
0.18 | 0.55 | 2.33 | 2.13 | |
Current Ratio |
0.38 | 0.74 | 2.50 | 2.30 | |
Net Debt/EBITDA |
0.15 | 0.07 | 1.92 | 2.13 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.53 | 0.27 | 0.89 | 1.93 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.18) | (0.69) | (0.86) | (1.53) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.18) | (0.69) | (0.86) | (1.53) | |
Cash per Share |
0.05 | 0.17 | 1.86 | 1.69 | |
Shareholders Equity per Share |
(0.07) | 0.08 | 1.61 | 1.43 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.07) | 0.08 | 1.61 | 1.43 | |
Free Cash Flow |
(2.78) | (7.60) | (3.57) | (6.78) | |
Working Capital |
(2.75) | (0.86) | 4.96 | 4.58 | |
Net Current Asset Value |
(9.03) | (7.48) | (1.99) | (2.68) | |
| Other line items | |||||
Average Payables |
3.36 | 1.39 | 1.74 | 1.31 | |
Average Assets |
17.06 | 21.46 | 29.21 | 25.48 | |
Average Common Equity |
4.35 | 5.98 | 12.90 | 8.90 |
Columns are period end dates